IGM Thinks Outside Oncology Box With Anti-Infective, Autoimmune Play
Executive Summary
The company created two new divisions focused on the new disease areas, bringing in former executives from Bristol Myers Squibb and Sanofi Pasteur.
You may also be interested in...
Imminent Madrigal, Viking Trial Readouts Will Shape NASH R&D Expectations
While neither company reported new data from their ongoing trials at AASLD, the firm’s competing THRβ agonists are viewed as leading lights in the non-alcoholic steatohepatitis competition.
Could REGEN-COV’s New US FDA Emergency Use Authorization Revive COVID-19 Prophylaxis Pipeline?
Regeneron’s neutralizing antibody cocktail earned the first post-exposure prophylaxis EUA for COVID-19, but the new use and dosing improvements need to overcome slow uptake under the original authorization for the COVID-19 treatment and the poisoned environment left by hydroxychloroquine controversies.
Executives On The Move: New Chief Financial Officers At AstraZeneca, Cyxone
New chief medical officers at IGM Biosciences, Compass Pathways, Passage Bio and more.